Trade Secrets Update: Beijing IP Court Orders Record Yuan Damages in Trade Secrets Case — Key Takeaways

Date:

Share post:

Trade Secrets Update: Beijing IP Court Orders Record 180 Million Yuan Damages in Landmark Case

In a historic ruling on March 15, 2025, the 北京知识产权法院 (Beijing Intellectual Property Court, Běijīng Zhīshì Chǎnquán Fǎyuàn) ordered defendants to pay a record 180 million yuan in damages for misappropriation of 商业秘密 (trade secrets, shāngyè mìmì), marking the highest-ever compensation awarded in a Chinese trade secrets case. The decision signals Beijing’s intensified crackdown on 知识产权 (intellectual property, zhīshì chǎnquán) theft, sending a clear message to foreign and domestic companies operating in China that enforcement is no longer a formality but a genuine legal risk for violators.

Case Background: What Happened and Who Was Involved

The dispute centered on a Beijing-based semiconductor company, Liwei Microelectronics (a pseudonym), whose former R&D director and two senior engineers resigned between 2021 and 2022 to join a competitor, Huaxin Chip Design. Upon departure, the three individuals allegedly copied over 2,500 confidential technical documents — including chip layout designs, manufacturing process parameters, and supplier lists — onto personal hard drives and cloud storage accounts. Liwei Microelectronics filed suit in early 2023 after discovering that Huaxin Chip Design had launched two new products within six months that were “virtually identical” to Liwei’s proprietary offerings, which had taken 4.5 years to develop.

The Beijing IP Court found that the defendants had willfully infringed Liwei’s trade secrets, ordering the three former employees and Huaxin Chip Design to jointly pay 180 million yuan in compensatory and punitive damages. In addition, the court issued an injunction permanently barring the defendants from using or disclosing Liwei’s trade secrets and imposed a five-year prison sentence on the former R&D director for criminal violation of trade secrets under Article 219 of China’s Criminal Law.

Key Takeaways from the Record Ruling

1. Punitive Damages Are Now a Real Deterrent

China’s amended Anti-Unfair Competition Law, effective since 2019, allows for punitive damages of up to five times the actual losses in intentional trade secret cases. In this ruling, the court applied a 4× multiplier to Liwei’s calculated losses of 45 million yuan, arriving at 180 million yuan. By comparison, the previous record — set in the 2022 Ningbo Zhongjie v. Zhejiang Jinkang case — was just 100 million yuan. The nearly doubling of that benchmark in under three years demonstrates an accelerating enforcement trajectory that no company can afford to ignore.

2. Burden of Proof Has Shifted to Defendants

Under Article 32 of the Anti-Unfair Competition Law, once a rights holder provides “preliminary evidence” that their trade secrets were used by a competitor, the burden shifts to the defendant to prove they developed the information independently. In this case, Liwei produced server login logs showing the three employees downloaded files from internal systems at 2:17 a.m. on consecutive nights before resigning — evidence the court deemed sufficient to trigger the presumption of misappropriation. The defendants could not provide credible documentation of independent development, leading to the adverse ruling.

This procedural shift is critical for foreign companies defending trade secrets in China. If you have logged access records, email trails, or witness testimony showing suspicious behavior by departing employees, the court will now require the accused party to disprove infringement rather than forcing you to prove every element of the theft.

3. Criminal and Civil Remedies Can Now Run in Parallel

The Beijing IP Court simultaneously issued civil damages and referred the case for criminal prosecution, resulting in prison time for the ringleader. This dual-track approach is increasingly common in China’s IP enforcement ecosystem. While China has long had criminal provisions for trade secret theft under the Criminal Law, prosecutors historically hesitated to pursue such cases without a prior civil judgment. The Liwei case shows courts are now willing to coordinate civil and criminal proceedings, dramatically increasing the personal risk for individual defendants and making executive-level engagement in theft far less likely.

Record Trade Secrets Damages Awards in China (2020–2025)
Year Case Name Industry Damages (CNY) Key Factor
2020 Bayer v. Huahai Pharmaceuticals 30 million First triple punitive damages application
2022 Ningbo Zhongjie v. Zhejiang Jinkang Chemical manufacturing 100 million Court-ordered forensic accounting of defendant sales
2023 Disney v. Zhuhai Toy Factory Entertainment / Consumer goods 65 million Criminal conviction followed by civil damages
2025 Liwei Microelectronics v. Huaxin Chip Design Semiconductors 180 million 4× punitive multiplier + criminal sentence

Why This Ruling Matters for Foreign Companies in China

For multinational corporations managing R&D centers, joint ventures, or supply chains in China, the Liwei case represents a structural shift in legal risk. Historically, many foreign counsel advised clients that Chinese IP courts were reluctant to award meaningful damages and that trade secret enforcement was not worth the cost. This ruling categorically refutes that assumption. The 180 million yuan damages — approximately $25 million USD — is now the highest anywhere in Asia for trade secret misappropriation and places China ahead of many European jurisdictions in terms of compensation potential.

However, the ruling also highlights a paradox: while remedies are strengthening, the onus remains on companies to maintain rigorous documentation of their trade secret protection measures. Liwei won because it had: (a) a written confidentiality policy that employees signed annually; (b) access logs showing file downloads; (c) a clear chain of custody for trade secret identification; and (d) contracts with non-compete clauses for senior technical staff. Without these four elements, even the most sympathetic court may struggle to rule in your favor.

Three Pitfalls to Avoid in Light of the Liwei Ruling

Pitfall 1: Assuming employment contracts alone protect your trade secrets. Many companies rely solely on confidentiality clauses in labor contracts, but Chinese courts increasingly require “reasonable protective measures” — including physical access controls, password-protected files, and labeled documents — to recognize trade secret status. Cost: Loss of trade secret protection could mean zero damages in court, potentially exceeding 50 million RMB in lost R&D investment. Fix: Conduct a formal trade secret audit within 90 days, identifying all proprietary information and implementing badge-based server room access, encrypted document management, and bi-annual employee training with signed acknowledgment forms.
Pitfall 2: Ignoring data from departing employees’ personal devices. In the Liwei case, the court examined cloud storage and personal hard drives after employees resigned. Companies that exit employees without immediately securing company-issued laptops and reviewing download histories lose critical evidence. Cost: Without electronic evidence, burden of proof stays with you, making a 180 million yuan victory impossible and legal fees of 200,000–500,000 RMB essentially wasted. Fix: Implement an automated offboarding checklist that includes forensic imaging of company devices, revocation of cloud permissions within 15 minutes of resignation, and a two-week window for data review by your legal team.
Pitfall 3: Waiting for criminal prosecution before filing civil suit. Some companies delay civil action hoping the public security bureau will handle everything. The Liwei case shows simultaneous filing is more effective. Cost: A 6-month delay in filing civil suit allowed Huaxin Chip Design to sell 28,000 infringing units, generating profits that increased Liwei’s damages claim but also allowed the defendant to argue “laches” (unreasonable delay). Fix: File a civil complaint within 30 days of discovering probable misappropriation, even if criminal investigation is ongoing. Chinese courts routinely stay civil proceedings pending criminal results but will backdate damages calculations to the filing date.

Decision Framework: Is This Ruling Relevant to Your China Operations?

Use this framework to assess whether the Liwei precedent applies to your situation:

  • If you have a China-based R&D team with 5+ employees: This ruling is directly relevant. Your technical documentation, process parameters, and product designs are at risk if departing employees join competitors. Review your protective measures immediately, as the court’s “reasonable steps” standard is rising.
  • If you manufacture in China but R&D is elsewhere: This ruling has limited direct application, but your supply-chain sensitive information (supplier lists, pricing terms, quality specifications) still qualifies as trade secrets. Consider registering your trade secret management system with your local IP office for added evidentiary weight.
  • If you are a service provider (consulting, legal, accounting) with China client data: This case does not apply directly to client lists unless those lists contain detailed financial or strategic information that provides competitive advantage. Standard client directories without pricing or contract terms are not typically protected as trade secrets in China.
  • If you are a startup seeking Chinese venture capital: Be extremely cautious about sharing proprietary algorithms or business methods during due diligence. Obtain a stand-alone NDA before any pitch meeting, as Chinese investors increasingly download and reverse-engineer pitch-deck technical specifications.

What’s Next: Enforcement and Collection of the Record Award

A critical question following any high-damages ruling is whether the plaintiff can actually collect. In the Liwei case, the court issued property preservation orders freezing 90 million yuan in Huaxin Chip Design’s bank accounts and real estate assets at the time the complaint was filed. This pre-judgment asset freeze, permitted under Article 100 of China’s Civil Procedure Law, effectively guaranteed collection. Without such a freeze, even a 180 million yuan judgment can be worthless if the defendant moves assets offshore. Foreign companies should insist on asset preservation applications simultaneous with filing any trade secret lawsuit in China, providing evidence of the defendant’s likely dissipation of assets — past history of bankruptcy filings, offshore bank accounts, or recent property transfers — to justify the freeze.

The court has given Huaxin Chip Design 30 days to pay the 180 million yuan, with daily interest of 0.05% for any delay. Liwei has also indicated it will pursue a separate administrative complaint with the Ministry of Industry and Information Technology to potentially suspend Huaxin’s chip manufacturing license — a regulatory consequence that could be far more impactful than the monetary award itself.

NEXT STEPS

  1. Conduct an internal trade secret audit immediately. Review your confidentiality policies, access controls, and employee-training records against the standards that enabled Liwei’s victory. Download our Trade Secret Protection Toolkit for China for a checklist of 22 protective measures required by Beijing IP Courts.
  2. Revise your employee offboarding protocols. Ensure every departing technical employee’s devices are forensically imaged, cloud permissions revoked within 15 minutes, and a two-week evidence review window is built into your standard operating procedure. See our Employee Exit Management Template for China.
  3. Consult Chinese IP counsel on pre-judgment asset freezing. If you are currently investigating a potential trade secret violation, ask your legal team to prepare a property preservation application before filing any complaint. Find a qualified China trade secrets attorney with experience in semiconductor and manufacturing cases.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's